Skip to main content
. 2021 Jun 30;7(2):172–177. doi: 10.5114/ceh.2021.106864

Fig. 1.

Fig. 1

Changes in hepatobiliary and lipid parameters show significant changes after one year of pemafibrate therapy. A) Aspartate aminotransferase (AST), B) alanine aminotransferase (ALT), C) alkaline phosphatase, D) γ-glutamyl transpeptidase (γ-GTP), E) low-density lipoprotein (LDL) cholesterol and F) triglyceride. *p < 0.05 compared to baseline